The Fly | BIOVF

Rare Disease Focus and Market Niche: Specialization in orphan drugs for rare diseases allows Sobi to operate in markets with high unmet medical need, less competition, and often higher pricing power due to the critical nature of their therapies.

Established Biopharmaceutical Portfolio: A strong existing portfolio of approved and commercialized treatments, particularly in hemophilia and immunology, provides stable revenue streams and a recognized presence in key therapeutic areas.

Global Commercial Footprint: An established commercial and distribution infrastructure across key international markets enables effective delivery and market penetration of its specialized therapies to diverse patient populations.

Reliance on Key Products: Sobi generates a substantial portion of its revenue from a limited number of key products; the loss of market exclusivity, increased competition, or adverse events affecting these products could materially impact financial performance.

Clinical and Regulatory Hurdles: The success of Sobi's pipeline depends on successful completion of clinical trials and securing regulatory approvals, which are complex, costly, and subject to significant uncertainty and delays.

Intense Market Competition: Despite focusing on rare diseases, Sobi faces significant competition from other pharmaceutical companies, biosimilar entrants, and new product developments that could reduce market share or put pressure on pricing.